Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG4040 plus peginterferon alfa-2a and ribavirin versus standard of care in treatment-naive genotype 1 chronic hepatitis C
2009-011121-13Phase 2Completed
- Sponsor
- Transgene SA
- Start
- Feb 2010
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatitis C virus infection comparing TG4040 plus standard of care with Standard of care (2 arms). Primary endpoint: Complete early virologic response. Started Feb 2010; status: completed.
02
Drugs
TG4040
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-011121-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011121-13.